<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02611648</url>
  </required_header>
  <id_info>
    <org_study_id>2015P000263</org_study_id>
    <nct_id>NCT02611648</nct_id>
  </id_info>
  <brief_title>Duodenoscope Disinfect Study</brief_title>
  <official_title>Prospective Randomized Double-blinded Trial Comparing Three Duodenoscope High- Level Disinfection and Sterilization Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <brief_summary>
    <textblock>
      This study is investigating the most effective way to sterilize duodenoscopes (&quot;scopes&quot;) used&#xD;
      at Beth Israel Deaconess Medical Center (BIDMC). Right now, BIDMC uses the standard method of&#xD;
      high level disinfection to sterilize scopes. Because infections have been passed by scopes at&#xD;
      other institutions in the U.S., the investigators are exploring whether or not adding two&#xD;
      different sterilization processes will reduce this risk of contamination.&#xD;
&#xD;
      Bacteria may be passed from a patient's intestines to the scope. Or, if the scope is&#xD;
      contaminated, bacteria may be passed from the scope to the patient. In order to understand&#xD;
      how bacteria are passed, the investigators will be taking samples of the patient's intestinal&#xD;
      bacteria to compare to the bacteria, if any, found on the scope.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design&#xD;
&#xD;
      This study is designed to evaluate the effect of supplementing standard high-level&#xD;
      disinfection with additional high level-disinfection or sterilization procedures on the&#xD;
      frequency of duodenoscopes contamination. Duodenoscopes will be randomly assigned to one of&#xD;
      three arms:&#xD;
&#xD;
        -  Standard high-level disinfection currently performed at BIDMC (standard HLD)&#xD;
&#xD;
        -  Standard high-level disinfection with an additional exposure time to disinfectant&#xD;
           (double HLD)&#xD;
&#xD;
        -  Standard high-level disinfection followed by ethylene oxide (HLD/ETO)&#xD;
&#xD;
      The study will be conducted with the following elements:&#xD;
&#xD;
        1. All duodenoscopes will be randomly assigned to a study arm before the duodenoscope is&#xD;
           used for an Endoscopic Retrograde Cholangiopancreatogram (ERCP) procedure included in&#xD;
           the study, including duodenoscopes introduced during the study.&#xD;
&#xD;
        2. All duodenoscopes used for ERCP will have the following cultures obtained in a sterile&#xD;
           fashion&#xD;
&#xD;
        3. Patient study consent for obtaining patient rectal surveillance and clinical cultures&#xD;
           will be obtained at the time of ERCP procedure consent among all patients undergoing&#xD;
           ERCP. Patients will be blinded to duodenoscope disinfection/sterilization assignment.&#xD;
&#xD;
        4. The ERCP procedure will be performed according to standard clinical practice. Among&#xD;
           patients consenting to specimen collection, a duodenal aspirate will be obtained during&#xD;
           the procedure.&#xD;
&#xD;
        5. Among consenting patients, a rectal surveillance swab will be collected&#xD;
           post-procedurally by ERCP staff.&#xD;
&#xD;
        6. After ERCP completion, current BIDMC-employed trained technicians will perform the&#xD;
           assigned disinfection/sterilization procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of contaminated duodenoscopes after using three different types of disinfection processes</measure>
    <time_frame>6 months</time_frame>
    <description>Compare the frequency of duodenoscope contamination after reprocessing using 3 different methods: standard high-level disinfection procedure with ortho-phthalaldehyde (standard HLD), double cycle of standard high-level disinfection (double HLD), and standard high-level disinfection followed by ethylene oxide (ETO) gas sterilization (HLD/ETO)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">541</enrollment>
  <condition>Endoscopic Retrograde Cholangiopancreatogram (ERCP)</condition>
  <arm_group>
    <arm_group_label>standard HLD</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard high-level disinfectant (metricide ortho-phthalaldehyde) currently performed at BIDMC (standard HLD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>double HLD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Double the exposure time of the standard high level disinfectant (metricide ortho-phthalaldehyde)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HLD/ETO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard high level disinfectant (metricide ortho-phthalaldehyde) followed by ethylene oxide</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Double HLD</intervention_name>
    <description>Standard high level disinfectant (metricide ortho-phthalaldehyde) with an additional exposure time to disinfect</description>
    <arm_group_label>double HLD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HLD/ETO</intervention_name>
    <description>Standard high level disinfectant (metricide ortho-phthalaldehyde) followed by ethylene oxide</description>
    <arm_group_label>HLD/ETO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A duodenoscope used for any intended ERCP procedure will be included in the study&#xD;
&#xD;
          2. All adult patients (age â‰¥18 years) scheduled to undergo ERCP will be offered&#xD;
             participation in patient specimen collection component of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients in whom ERCP or endoscopy with a duodenoscope is medically contra-indicated&#xD;
             will not be included in the patient specimen collection portion of the study&#xD;
&#xD;
          2. Patients with surgically altered anatomy in whom ERCP is performed using an&#xD;
             enteroscope (and not a duodenoscope) will not be included in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>November 12, 2015</study_first_submitted>
  <study_first_submitted_qc>November 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2015</study_first_posted>
  <last_update_submitted>March 11, 2017</last_update_submitted>
  <last_update_submitted_qc>March 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Mandeep Sawhney</investigator_full_name>
    <investigator_title>Mandeep Sawhney, MD</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

